PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-75.16%
Negative net income growth while VET stands at 25.13%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-0.31%
Negative yoy D&A while VET is 3.84%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-724.32%
Negative yoy deferred tax while VET stands at 130.17%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
No Data
No Data available this quarter, please select a different quarter.
-62.99%
Both reduce yoy usage, with VET at -628.94%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.99%
Negative yoy usage while VET is 0.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
101.96%
Some yoy increase while VET is negative at -411.39%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
6.77%
Some CFO growth while VET is negative at -94.24%. John Neff would note a short-term liquidity lead over the competitor.
31.44%
CapEx growth well above VET's 8.79%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
-112.12%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
80.28%
Purchases growth of 80.28% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-31.44%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
24.06%
We have some outflow growth while VET is negative at -974.75%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
26.90%
We have mild expansions while VET is negative at -0.96%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
850.00%
Stock issuance far above VET's 169.40%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.